News
Author: admin als-handoff
-
Achieve Life Sciences Reports Financial Results for Third Quarter and Provides Corporate Update
Company to host conference call at 4:30 PM EST today, Thursday, November 9, 2023. SEATTLE, Wash and VANCOUVER, British Columbia, November 9, 2023 (GLOBE NEWSWIRE) — Achieve Life Sciences, Inc. (NASDAQ: ACHV), a late-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, today announced third quarter…
-
Achieve Life Sciences to Announce Third Quarter 2023 Financial Results and Host Conference Call and Webcast on November 9, 2023
SEATTLE, WA and VANCOUVER, British Columbia, October 26, 2023 (GLOBE NEWSWIRE) — Achieve Life Sciences, Inc. (NASDAQ: ACHV), a late-stage clinical pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, today announced it will report its third quarter 2023 financial results and provide an update on the…
-
Achieve Life Sciences Announces Participation at Upcoming Investor Conferences
SEATTLE and VANCOUVER, British Columbia, October 3, 2023 (GLOBE NEWSWIRE) — Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, today announced that management will be participating at two upcoming investor conferences. Meetings will be conducted at the JonesTrading…
-
Achieve Life Sciences Announces Presentation of Cytisinicline E-Cigarette Cessation (ORCA-V1) Results at Society for Research on Nicotine and Tobacco Europe (SRNT-E) Annual Meeting
SEATTLE and VANCOUVER, British Columbia, Sept. 11, 2023 (GLOBE NEWSWIRE) — Achieve Life Sciences, Inc. (NASDAQ: ACHV), a late-stage clinical pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, today announced that Phase 2 ORCA-V1 trial results will be presented at the Society for Research on Nicotine…
-
Achieve Life Sciences Announces Participation at Upcoming Investor Conferences
SEATTLE and VANCOUVER, British Columbia, September 7, 2023 (GLOBE NEWSWIRE) — Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, today announced that John Bencich, CEO of Achieve, will be participating at three upcoming conferences. H.C. Wainwright 25th Annual…